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OBJECTIVE To investigate the antiproliferative and apoptogenic
activities of peptide extracted from the Chinese toad (Bufo bufo
gargarizans) skin (TSP) and its effects on hepatocarcinoma cell line.
METHODS MTTassaywas usedto detecttheeffects ofTSP(50 mg/mL
and 5 mg/mL) on the proliferation and viability of Hepatocarcinoma
cell line (HepG2) and liver cell line (L-02); Flow cytometry was used in
DNA content analysis to determine the cell distribution in different
phases of cell cycle; Annexin V-FITC/PI stained fluorescence-activated
cell sorter (FACS) and transmission electron microscope (TEM) were
used to detect the apoptosis of the treated cells.
RESULTS TSP could not suppress the proliferation and viability of
normal liver L-02 cells, but strongly inhibited the proliferation and
viability of HepG2 cells; TSP (50 mg/mL) primarily arrested the HepG2
cells at G1 phase of the cell cycle; TSP (50 mg/mL) induced apoptosis
in HepG2 cells and enhanced the effects of 5-Fu.
CONCLUSION TSP has potent antineoplastic activity against
human hepatocarcinoma cells with little toxicity to normal liver
cells and can enhance the effects of 5-Fu.
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Introduction
Cancer is a complex multifactorial genetic disease. Transformed cells
are controlled by certain genes which regulate proliferation of normal
cells. Nowadays, chemotherapy is one of the most important modalities
for cancer treatment. However, the effects of the chemo-drugs on most
solid tumors are disappointing.
Drug discovery against cancer is ventured throughout the world
especially from the natural products. The skin of the amphibian skin
fulfils a wide range of functions necessary for the amphibian’s survival.
It is evident that amphibians, such as frogs and toads possess various
bioactive substances in their skin
[1]. Earlier investigation in the Indians
revealed that Indian toad (Bufo melanostictus) skin extract was
pharmacologically potent, including immunomodulatory and antineo-
plastic activities in Ehrlich ascites carcinoma bearing mice
[2,3].Up to
now, a number of cationic peptides extracted from the skin of various
amphibians have been isolated and reported that some of their
derivatives show anti-tumour activity with little toxicity against non-
malignant cells either by triggering apoptosis
[4–6] or by forming ion
channels/pores
[7]. Furthermore, some peptides were found to be
cytotoxic against Multidrug Resistance (MDR) cancer cells. The
discovered peptides in the amphibian has encouraged further study
and exploitation for novel amphibian biochemicals.
Clin Oncol Cancer Res (2011) 8: 149–154 149
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treated in whole as drugs to treat tumours, and its
anticancer activities particularly interest many cancer
researchers. Bufalin is one of the prominent components
of bufadienolides which was isolated from ‘‘Chan Su’’ a
Chinese traditional medicine. Its pharmacological activ-
ities, as an anticancer agent, have been reported. A
number of researches focusing on the anticancer activ-
ities of Chinese toad have been in progress around the
world to analyze the biogenic amines, bufodienolides,
alkaloids and steroids isolated from the skin secretions,
but few published evidences are available on its skin
extract. The present communication is an approach to
study the anticancereffects of Chinese toad skin extract
on hepatocarcinoma cells.
Materials and Methods
Preparation and collection of toad skin extract
(named as ‘TSP’)
Chinese toads were collected from the local farmlands
during October and November. The skins of the caught
adult toads were prepared for use. The skins overlying
the abdomen, thorax, back and legs of the toads were
surgically removed, and then the animasl were subse-
quently sacrificed. The skins were homogenized in a
chilled blender, in which 4 vol (based on initial skin
weight) of 0.14 M NaCl (pH 6.0), 5 mM EDTA and 0.2%
Triton X-100 were added just prior to homogenization.
The foamy gray homogenate was centrifuged at 18,000 g
for 20 min, and the clear supernatant was heated in
water at 50uC for 10 min, centrifuged at 8,000 g for
15 min, and then the obtained precipitate was discarded.
The supernatant was concentrated and desalinated in an
ultrafiltrate centrifuge tube for ultrafiltration, and finally
was frozen and dried in lyophilizer. Crude fraction was
collected and further purified using C18 reversed-phase
HPLC. After that, peptide molecular mass was analyzed
through a MALDI-TOF mass spectrometer.
Human cell cultures
HepG2, a kind of human cancer cells, and L-02, a kind of
normal liver cells were respectively cultured in RPMI1640
and DMEM medium which was supplemented with
10% fetal bovine serum (heat inactivated), penicillin
(100 units/mL) and streptomycin (100 mg/mL). Cell
lines were maintained in a humidified incubator with
5% CO2 at 37uC and passaged twice a week started at an
initial density of 1610
6 cells/mL.
MTT assay
The MTT cell proliferation assay was performed accord-
ing to the method described by Kawada et al.
[8] One
hundred and fifty mL of cancer cells (HepG2) suspension
in RPMI 1640 supplemented with 10% fetal calf serum
containing 1610
5 cells was seeded to each well of a 96-
well microtiter plate. The cells were cultured in the
presence and absence of TSP (5 mg/mL, 50 mg/mL), 5-Fu
(25 mg/mL) or TSP+5-Fu, respectively. The plate was
incubatedin the humidified incubatorcontaining 5%CO2,
at 37uC in for 48 h. Then, 20 mL of MTT (5 mg/mL) was
added to each well and following that the plate was
incubated again in the humidified incubator with 5% CO2
at 37uC in a for 4 h. Next, 150 mL of DMSO was added to
each well to dissolve the formazan crystal that formed.
The optical density (OD) was recorded at 490 nm. Growth
inhibition rate (%) was calculated as follows: (1-OD of
treated sample/OD of control sample) 6 100%.
Cell cycle analysis
For analyzing distribution of the cells in different phases
of cell cycle, control cells and TSP-treated cancer cells
(1610
6 cells per group) were washed with PBS 24 h after
TSP treated (5 mg/mL, 50 mg/mL), fixed in 70% ethanol,
stained with 10 mL of propidium iodide(100 mg/mL)and
then treated with 10 mL of RNaseA (5 mg/mL). The DNA
content of the cells was subsequently analyzed using
flow cytometry (Becton Dickinson, USA) with standard
protocols. The distribution of DNA content was
expressed using the percentage of the cells in each phase
of G1, S, and G2.
Annexin V-FITC/PI stained fluorescence-activated
cell sorter (FACS) analysis
The cells were harvested by trypsinization, washed twice
with cold PBS, and centrifuged at 1,000 rpm for 5 min.
The supernatant was discarded and the pellet was
resuspended in binding buffer at a density of 1.0610
5–
1.06l0
6 cells per mL. Then, 100 mL of the sample solution
was transferred to a 5 mL culture tube, and incubated
with 5 mL of FITC-conjugated Annexin V and 5 mLo fP I
at room temperature in the dark for 15 min. Following
that, 400 mL of binding buffer was added to each sample.
The samples were subsequently analyzed using FACS
and Cell Quest Research Software.
Transmission electron microscope (TEM)
The cells were fixed in the mixture of 0.1 M phosphate
buffer with 2.5% glutaraldehyde and 4% paraformalde-
hyde. The samples were then fixed in 1% osmium tetroxide,
dehydrated in graded acetones, and flat-embedded in Epon
plastic 812 in a cross-sectional orientation. Then 85-nm
sections which were obtained after stained with 0.25% lead
citrate and 5% uranyl acetate in 50% acetone were observed
a n dp h o t o g r a p h e du n d e raJ E O L1 0 0 C Xt r a n s m i s s i o n
electron microscope (Los Angeles, CA, USA).
Statistical analysis
SPSS 13.0 was used for statistical analysis. Results based
on four replicates per experimental group. For all the
150 Clin Oncol Cancer Res (2011) 8: 149–154measurements, one-way ANOVA followed by Student’s
Newman Keuls (SNK) test was used to assess the
statistical significance of difference between control and
TSP-treated, A P-value , 0.05 was considered statisti-
cally significant.
Results
Purification and molecular characterization of the
peptides
The crude fraction was divided into 6 peaks by C-18
HPLC column. The peak indicating anticancer activity
was collected and the molecular mass was analyzed
through MALDI-TOF mass spectrometer (Fig.1).
Effects of TSP, 5-Fu, combination of TSP and 5-Fu on
the proliferation of HepG2 and L-02 cell lines
TSP produced dose-dependent inhibition effects on the
growth of HepG2 cells compared to untreated control
cells (P , 0.05). The inhibition rate of the cells treated
with TSP (5 mg/mL) combined with 5-Fu (25 mg/mL)
was significantly greater (P , 0.05) than that of the cells
treated with TSP (5 mg/mL) or 5-Fu (25 mg/mL) alone.
The effect of TSP on L-02 cell proliferation was mild.
(Table 1, Fig.2).
Cell cycle analysis
The distribution of the cells in different phases of cell
cycle generated by flow cytometry revealed that HepG2
Fig.1. TSP molecular mass analyzed through MALDI–TOF mass spectrometer.
Table 1. Inhibition ratio of the cells treated with TSP, 5-Fu, combination of TSP and 5-Fu on the proliferation of HepG2 and L-02
cell lines
Type of cells Time (h)
Inhibition ratio (%)
TSP (5 mg/mL) TSP (50 mg/mL) 5-Fu (25 mg/mL) TSP (5 mg/mL) +5-Fu
HepG2 24 11.3¡0.11 29.6¡0.16 31.3¡0.19
# 46.9¡0.11
m
48 10.8¡0.13 52.3¡0.14 56.1¡0.13
# 65.6¡0.12
m
72 15.0¡0.32 50.8¡0.12
* 64.4¡0.16
# 71.5¡0.18
m
L-02 24 9.1¡0.09 12.9¡0.19 19.6¡0.17 28.4¡0.14
48 10.8¡0.13 14.9¡0.16 20.0¡0.12 29.6¡0.13
72 12.3¡0.17 14.5¡0.14 21.4¡0.20 30.9¡0.10
# vs.* :P,0.05,m vs.# : P,0.05
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24 h exhibited a distribution of 67.3%, 18.4%, 14.3% and
58.0%, 29.2% and 12.8% of the HepG2 cells in the G1, S
and G2 phases of the cell cycle, respectively. On the other
hand, the HepG2 cells which were untreated showed a
distribution of 56.1%, 30.9% and 13.0% of cells in G1, S
and G2 phases of the cell cycle,respectively (Fig.3). The
HepG2 cells treated with TSP (50 mg/mL) showed arrest
in the G1 phase of the cell cycle and a decreased number
of the cells in the S phase.
Annexin V-FITC/PI stained fluorescence-activated
cell sorter analysis
Annexin V-FITC and PI stained cells were analyzed using
FACS to determine the percentage of survived or
apoptotic cells after treated with TSP (50 mg/mL), 5-Fu
(25 mg/mL) or TSP (5 mg/mL) + 5-Fu for 24 h. TSP
(50 mg/mL) treatment induced apoptosis of the L-02 cells
for 7.14%, and of HepG2 cells for 21.86%. The apoptosis
rate of the hepatocarcinoma cell lines treated with TSP +5-
Fu was higher than that treated with 5-Fu alone (Fig.4).
Transmission electron microscope (TEM)
Hepatocarcinoma cell lines treated with TSP (50 mg/mL)
showed changes in its morphology(Fig.5).
Discussion
Hepatocellular carcinoma (HCC) is one of the most
common malignant tumors worldwide. As sufficient
doses of chemotherapy drugs are limited due to poor
Fig.2. Cell growth inhibition (MTT
assay) at 24 h, 48 h and 72 h in (a)
HepG2 and (b) L-02 cells treated with
TSP(50 mg/mL), 5-Fu (25 mg/mL), 5-Fu
(25mg/mL)+ TSP (5 mg/mL). Values
represent the mean¡SDAsterisk (m)
sign indicates statistically significant
values compared to (#)(P , 0.05)
Fig.3. Effect of TSP on the cell distribution in different
phases of the cell cycle. The mean percentage of the cells in
G1, S and G2 phases of cell cycle are presented. Error bars
represent SD. Asterisk (m) sign indicates statistically signifi-
cant values compared to (#)( P , 0.05).
Fig.4. TSP (50 mg/mL), 5-Fu (25 mg/mL) and TSP (5 mg/mL) + 5-
Fu induced apoptosis of HepG2 and L-02 cells. Values
represent the mean¡SD. Asterisk (*) sign indicates statisti-
cally significant values compared to (g)( P , 0.05); Plus (+)
sign indicates statistically significant values compared to
Asterisk (*) (P, 0.05).
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sensitivity to anti-cancer agents, chemotherapy plays
little role in the overall survival of the HCC patients.
Novel agents which have greater targeting on HCC but
lower toxicity for normal liver cells, are seen as a
direction of enormous potential. Up to now, a number of
agents extracted from the skin of various amphibians
have been analyzed and found to have antitumor activity
with little toxicity against non-malignant cells
[9–11].
It is now well established that the reduced capacity of
tumor cells undergoing cell death through apoptosis, plays
a key role both in the pathogenesis of cancer and in
therapeutic failure
[12–16]. In the present study, the peptide
extracted from the Chinese toad (Bufo bufo gargarizans)
skin (TSP)showed strong inhibition to the proliferation and
viability of the HepG2 cells. As shown in the results, TSP
was a moderate inhibitor suppressing the proliferation of
the L-02 cells in culture, and it could enhance the effects of
5-Fu. Analyses through flow cytometry and transmission
electron microscope (TEM) showed that TSP could induce
apoptosis of HepG2cells. The antiproliferative effect of TSP
can be attributed to the ability of TSP to hold the cell cycle
at the G1 phase, and as a result, prevent further cell
proliferation and initiate apoptotic signaling. The fact that
TSP has two opposite effects on tumor cells and on normal
cells is intriguing. The exact mechanism remains to be
clarified. Bufalin, which is one of Chinese toad (B. b.
gargarizans) skin extract preparation, may induce apopto-
sis in human cancer cells by up or down-regulating some
genes expression
[17–21]. It has been reported that some
peptides isolated from amphibian skin show antitumor
activity with little toxicity against nonmalignant cells,
either by triggering apoptotic process
[4,5,22,23] or by forming
ion channels/pores
[6]. In this study, The results from flow
cytometric analysis, TEM and the outcome of the HepG2
cellsarrested at G1, all demonstratethe apoptogenic nature
of TSP, whereas the inhibition rate of cell growth,
decreased absorbance of TSP-treated HepG2 show the
antiproliferation and cytotoxic activity of TSP.
In recent years, combination therapy in cancer treatment
or in cancer prevention has been widely recognized as an
effective approach to maximize treatment effects
[24,25].T h e
data from our study demonstrate that TSP acts synergis-
ticallywith5-Futoinhibitthegrowthandinduceapoptosis
of HepG2 cells, suggesting that this strategy could be an
effective way to destroy hepatocarcinoma cells. However,
the mechanism of such enhancement remains unclear and
the research on the characteristics of TSP is in progress.
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